Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Intercept Pharmaceut (ICPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,261,886
  • Shares Outstanding, K 29,694
  • Annual Sales, $ 179,800 K
  • Annual Income, $ -309,240 K
  • 60-Month Beta 1.62
  • Price/Sales 19.02
  • Price/Cash Flow N/A
  • Price/Book 178.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -2.58
  • Number of Estimates 11
  • High Estimate -1.95
  • Low Estimate -3.12
  • Prior Year -3.22
  • Growth Rate Est. (year over year) +19.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
91.50 +19.50%
on 02/26/19
116.30 -5.99%
on 03/21/19
+15.10 (+16.02%)
since 02/25/19
3-Month
87.60 +24.82%
on 12/26/18
131.87 -17.09%
on 02/19/19
+22.87 (+26.45%)
since 12/24/18
52-Week
58.03 +88.42%
on 03/28/18
133.74 -18.24%
on 10/01/18
+48.61 (+80.04%)
since 03/23/18

Most Recent Stories

More News
Conatus (CNAT) Declines on Failure of NASH Fibrosis Study

Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

CNAT : 1.20 (-6.25%)
NVS : 93.31 (-0.12%)
GILD : 63.79 (+0.03%)
ICPT : 109.34 (-0.46%)
Intercept Pharma Set to Possibly Pullback After Yesterday's Rally of 1.34%

Intercept Pharma (NASDAQ:ICPT) traded in a range yesterday that spanned from a low of $104.66 to a high of $106.28. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high...

ICPT : 109.34 (-0.46%)
April 26th Options Now Available For Intercept Pharmaceuticals (ICPT)

Investors in Intercept Pharmaceuticals Inc saw new options become available today, for the April 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ICPT options...

ICPT : 109.34 (-0.46%)
Intercept to Present at Upcoming Investor Conferences

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 109.34 (-0.46%)
New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of American Tower Corporation (REIT)...

MIME : 46.02 (+1.68%)
LOW : 106.03 (+1.03%)
AMT : 195.69 (+1.05%)
LYV : 62.82 (-0.21%)
CHRS : 14.13 (-1.33%)
ICPT : 109.34 (-0.46%)
SmarTrend Watching for Potential Pullback in Shares of Intercept Pharma After 4.02% Gain

Intercept Pharma (NASDAQ:ICPT) traded in a range yesterday that spanned from a low of $102.01 to a high of $103.75. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high...

ICPT : 109.34 (-0.46%)
Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus

Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.

MRK : 82.35 (+0.07%)
MDGL : 130.72 (-2.65%)
GILD : 63.79 (+0.03%)
ICPT : 109.34 (-0.46%)
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update

Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH study

ICPT : 109.34 (-0.46%)
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

VRTX : 183.85 (+1.28%)
CLVS : 23.04 (-7.25%)
GILD : 63.79 (+0.03%)
ICPT : 109.34 (-0.46%)
ALKS : 33.38 (-1.71%)
Intercept to Announce Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce...

ICPT : 109.34 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ICPT with:

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Key Turning Points

2nd Resistance Point 112.94
1st Resistance Point 111.14
Last Price 109.34
1st Support Level 107.32
2nd Support Level 105.30

See More

52-Week High 133.74
Last Price 109.34
Fibonacci 61.8% 104.82
Fibonacci 50% 95.89
Fibonacci 38.2% 86.95
52-Week Low 58.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar